New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
12:39 EDTSGYPSynergy Pharmaceuticals price target raised to $13 from $7 at Cantor
Cantor increased its target on Synergy after the company reported results from a Phase III trial of its chronic constipation treatment, plecanatide, that the firm views as positive. The firm increased its E.U. and Japanese sales estimates for the drug, and it sees the company as a takeover target. Cantor believes that Synergy has multiple upcoming positive catalysts and it maintains a Buy rating.
News For SGYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
09:16 EDTSGYPOn The Fly: Pre-market Movers
Subscribe for More Information
08:06 EDTSGYPSynergy Pharm says analysis shows Phase 2 SP-333 trial met primary endpoint
Subscribe for More Information
November 10, 2014
16:30 EDTSGYPGreat Point Partners reports 6.35% passive stake in Synergy Pharmaceuticals
16:11 EDTSGYPSynergy Pharmaceuticals reports Q3 EPS (24c), consensus (28c)
Synergy's cash, cash equivalents and available-for-sale securities balance as of September 30 was $32.7M as compared to $68.1M on December 31, 2013.
November 7, 2014
16:40 EDTSGYPPointState Capital reports 6.4% passive stake in Synergy Pharmaceuticals
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use